Published on
Updated
Reading 1 min.
This is an announcement that somewhat surprised the world of medicine: the French laboratory Sanofi announced, on October 27, that it would abandon its consumer health activity at the end of 2024. A way for the laboratory to refocus on innovative medicines and vaccines.
Doliprane but also Mucosolvan and Allegra: these drugs will soon be abandoned by the giant Sanofi, which intends to refocus its activity on innovative drugs and vaccines. Sanofi is therefore abandoning its entire consumer health branch.
A desire displayed for several years
This operation “will make it possible to further adapt the management and allocation of resources to the needs of the biopharmaceutical activity” Or ““Longer-term value creation opportunities and operational levers have been identified to support the acceleration of research and development investments” explains the group in a press release.
A long-anticipated strategy, in fact, because Sanofi had already announced in 2019 the creation of an autonomous commercial entity to bring together its non-prescription medicines and food supplements, named Opella.
Towards the end of Doliprane?
This decision by the French laboratory is intended to refocus its strategy on research and development and to focus on Dupixent, a flagship treatment used against eczema or asthma, which currently represents its main source of income.
In addition to its food supplements such as Novanuit for sleep, Sanofi is also abandoning Mucosolvan, used to treat coughs, and Doliprane, the most prescribed drug in the world. Will it disappear? The laboratory has not confirmed anything at the moment. On the contrary, it has just injected 20 million euros into the Lisieux site, in Calvados, to increase the production of Doliprane from 2025. To be continued, therefore…